AMI patients with non-severe coronary artery stenosis.
Conditions
Interventions
The experimental group:Guideline-recommended standard medical therapy
The control group:DES implantation plus guideline-recommended standard medical therapy
Sponsors
The Second Affiliated Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Male or female patients aged >=18 years and 2.5 mm and <=4.0 mm; 5. Patients or a legally authorized representative must provide written Informed Consent prior to any study related procedure.
Exclusion criteria
Exclusion criteria: 1. Clinical exclusion criteria: (1) Severe cardiac dysfunction (Killip/NYHA class >= 3) or LVEF =2.0 mg/dL] without regular dialysis (patients with chronic renal insufficiency on regular dialysis may be considered for enrollment); (7) Active liver disease, defined as known infectious, neoplastic, or metabolic liver lesions, with ALT and AST >3× upper limit of normal (ULN); (8) Previous history of CABG or PCI for the culprit lesion; (9) Patients with other concurrent severe diseases and an expected life expectancy of =70% or planned revascularization; (2) Left main coronary artery lesion with DS >=50%; (3) Culprit lesion is a true bifurcation lesion requiring a two-stent strategy; (4) Long lesion (planned stent length >60 mm); (5) Culprit lesion with dissection, false lumen, or other conditions necessitating stent implantation; (6) Target lesion has undergone pre-treatment (e.g., balloon dilation, rotational atherectomy, etc.). 3. Functional sub study: (1) Individuals who are allergic to adenosine triphosphate (ATP) or any component in its preparations; (2) Second and third degree atrioventricular block, sick sinus syndrome (without artificial pacemaker protectors); (3) Patients with bronchial asthma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Target Lesion Failure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Bleeding Academic Research Consortium (BARC) type 3 and 5;Target Lesion Revascularization;Target vessel myocardial infarction;Rehospitalization for Unstable angina pectoris;Contrast-induced acute kidney injury (CI-AKI);Cardiovascular death;Target vessel Revascularization;Seattle Angina Questionnaire(SAQ);Definite or probable in-stent thrombosis;Stroke;Rehospitalization for Heart Failure;Ischemia Driven Target Lesion Revascularization;Myocardial infarction;The first occurrence of all-cause death and readmission due to heart failure.;Microcirculation resistance index to assess the incidence of coronary microvascular dysfunction.;All-Cause death;Procedure-related myocardial infarction;Major Adverse Cardiovascular and Cerebrovascular Events;Coronary Revascularization; | — |
Countries
China
Contacts
Public ContactBoYu
The Second Affiliated Hospital of Harbin Medical University
Outcome results
None listed